key: cord-0735885-1rhab28n
authors: Takada, Kazuki; Takamori, Shinkichi; Miura, Naoko; Shikada, Yasunori; Shimokawa, Mototsugu
title: Re: COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)
date: 2021-08-26
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.07.046
sha: 587918a5d05d2a3206086cf1fc9940347e7ec513
doc_id: 735885
cord_uid: 1rhab28n

nan

Cancer on 29 June 2021 [1] . The authors conducted a worldwide survey focused on 4 neuroendocrine neoplasms in patients with COVID-19 and found that most of them 5 (more than 80% of the study cohort) overcame COVID-19 without short-term sequelae 6 or requiring intensive care or discontinuation of systemic oncological therapy. However, 7 7.8% of these patients died of COVID-19 [1] . They concluded that their findings could 8 assist decisions on clinical management of neuroendocrine neoplasms patients during 9

the COVID-19 pandemic [1] . We agree that the results of this study are informative for 10 clinicians, especially those involved in the treatment of patients with neuroendocrine 11 neoplasms. However, we believe that the article was lacking some important data; 12 namely, COVID-19 vaccine uptake and the time of COVID-19 diagnosis in this study 13 cohort. 14 The COVID-19 vaccine is expected to be a vital tool for managing the COVID-19 15 pandemic; however, the refusal of both some healthy individuals and cancer patients has 16 J o u r n a l P r e -p r o o f become problematic [2] [3] [4] . There are likely differences in vaccine acceptance rates 1 between countries; however, Di Noia et al. reported that 102 of 914 cancer patients at a 2 single center in Italy refused vaccination (11.2%, 95% CI 9.1-13.2) [2] . In that study, 3 the main reasons for vaccine refusal were as follows : 1) 

COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a 3 worldwide survey (The INTENSIVE study)

The first 6 report on Covid-19 vaccine refusal by cancer patients in Italy: early data from a 7 single-institute survey

Public acceptance of COVID-19 9 vaccines: cross-national evidence on levels and individual-level predictors using 10 observational data

COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review 12 of Vaccine Acceptance Rates. Vaccines (Basel)

Commentary: SARS-CoV-2 vaccines and cancer patients

Annals of oncology : official journal of the European Society for Medical Oncology

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for

SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA oncology

Comparison of COVID-19 Vaccine Approvals at the US

Food and Drug Administration, European Medicines Agency, and Health Canada

Association of clinical factors and recent anticancer therapy with COVID-19 severity 11 among patients with cancer: a report from the COVID-19 and Cancer Consortium